Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors

#901

Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).

Aim(s): To evaluate the efficacy of the long-acting SSA octreotide in MEN1 patients with early stage duodeno-pancreatic NETs.

Materials and methods: Forty MEN1 patients were retrospectively evaluated. Twenty patients with evidence of one or more MEN1-related duodeno-pancreatic NETs <20 mm in size (age range 26-61 yrs) were treated with octreotide LAR as first-line therapy. Treatment duration ranged 12-75 months. At the baseline radiological evaluation, multiple duodeno-pancreatic NETs (range 1-8, size 3–18 mm) were detected.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L,

Keywords: somatostatin analogues, MEN1, neuroendocrine tumors, pancreatic neuroendocrine tumor,